广州艾奇西新药研究

Guangzhou H&J New Drug Research is a clinical-stage biotechnology company based in Guangzhou, China, specializing in the discovery and development of innovative small molecule therapeutics. The company focuses on high-prevalence conditions, including metabolic disorders such as type 2 diabetes and gout, as well as oncology and inflammatory diseases. H&J utilizes its proprietary drug discovery platform to advance internal pipeline programs and provide contract research services (CRO) to global partners. Their lead candidates, such as the GPR119 agonist HJ-001 and the URAT1 inhibitor HJ-011, have progressed into clinical development. The firm is led by a team of experienced scientists with backgrounds in international pharmaceutical R&D.